More Evidence for Waning Immunity Associated with Pfizer-BioNTech’s BNT162b2

A team of Israeli-researchers led by Dr. Regev-Youchay from Sheba Medical Center conducted a 6-month longitudinal prospective study monitoring 4868 health care worker participants from December 2020 through July 2021. Their mission: test the monthly presence of anti-spike IgG and neutralizing bodies as a means of better understanding the durability of the Pfizer-BioNTech mRNA vaccine called BNT162b2. Put another way, how well vaccines actually work overtime is not understood. They found that at six months after receipt of a second dose of the BNT162b2 vaccine, the humoral response declined substantially, with this observation greater among men, the elderly (65+), and among the immunocompromised.

TrialSite provides a brief breakdown of this study. The longitudinal, prospective study timeline indicates that the findings would apply to the wild-type virus and others that may have been present. The study was published in the New England Journal of Medicine.

How many participants?

4,868

Participant (Health worker) demographics

Physician 18%; Nurses or nurse aids 27%; Paramedical 21%; Administrative or logistic 34%.

The Real-World Site

Sheba Medical Center, large t...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee